Table 4 Clinical remission in JIA patients treated with DMARD according to treatment group. Prospective study results
|  | SDMARD alone n = 33 (43%) | SDMARD combined n = 6 (8%) | SDMARD BDMARD combined n = 23 (30%) | BDMARD alone n = 14 (18%) | Clinical remission n = 76 | p |
|---|---|---|---|---|---|---|
Female sex a, n (%) | 24 (73) | 4 (67) | 8 (35) | 9 (64) | 45 (59) | 0.037 |
Persistent oligoarticular a, n (%) | 19 (91) | 6 (100) | 4 (57) | 2 (50) | 31 (82) | 0.048 |
ANA positivity a, n (%) | 26 (79) | 6 (100) | 12 (52) | 6 (43) | 50 (66) | 0.013 |
HLA B27 absence a, n (%) | 31 (94) | 0 | 12 (52) | 8 (57) | 57 (75) | 0.005 |
Uveitis absence a, n (%) | 27 (82) | 2 (33) | 21 (91) | 13 (93) | 63 (83) | 0.006 |
Biologic DMARD a, n (%) | ||||||
 Etanercept | 0 | 0 | 5 (36) | 10 (71) | 15 (54) | 0.040 |
DMARD dose tapering a, n (%) | 29 (88) | 3 (50) | 14 (61) | 11 (79) | 57 (75) | 0.050 |